Lukas Rob
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lukas Rob has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Helena Robova
Department of Obstetrics and Gynecology, 2nd Medical Faculty Charles University Prague, Czech Republic
9 shared publications- Petr Skapa
Department of Pathology and Molecular Medicine, 2nd Medical Faculty Charles University Prague, Czech Republic
9 shared publications Marek Pluta
Department of Obstetrics and Gynecology, 2nd Medical Faculty Charles University Prague, Czech Republic
6 shared publicationsPavel Strnad
Department of Obstetrics and Gynecology, 2nd Medical Faculty Charles University Prague, Czech Republic
3 shared publications- Anna Fialová
Sotio, Prague, Czech Republic
2 shared publications - Helena Robova
Department of Obstetrics and Gynecology, 2nd Medical Faculty, Charles University, V Uvalu 84, 150 00, Prague 5, Czech Republic,
2 shared publications
Latest Publications
- 18 April 2015
- Published by Springer Nature in Current Oncology Reports
- Vol. 17 (5) , 1-5
Review of Neoadjuvant Chemotherapy and Trachelectomy: Which Cervical Cancer Patients Would Be Suitable for Neoadjuvant Chemotherapy Followed by Fertility-Sparing Surgery?
The number of patients given neoadjuvant chemotherapy (NAC) followed by fertility-sparing surgery in cervical cancer is still scarce. Only a few centres perform these procedures, and thus, such procedures remain largely in the experimental stage. Patients that do not fulfil the criteria for standard fertility-sparing procedure can be included in studies with NAC followed by fertility-sparing procedure. We must consider that both oncological and pregnancy outcomes are important. Patients with only microscopic disease after NAC are apparently the best candidates for fertility-sparing surgery. Current data are not sufficient to identify the optimal procedure after NAC [abdominal radical trachelectomy (ART) or vaginal radical trachelectomy (VRT) or simple trachelectomy]. Some evidence suggests that pregnancy outcome is better after simple trachelectomy as compared with VRT or ART. Long-term results regarding oncological outcome for this concept are still lacking. Adjuvant chemotherapy in patients with histopathological risk factors (lymphovascular space involvement (LVSI), macroscopic residual disease) would decrease a risk of recurrence.
- 18 April 2015
- Published by Springer Nature in Current Oncology Reports
- Vol. 17 (5) , 1-5
Review of Neoadjuvant Chemotherapy and Trachelectomy: Which Cervical Cancer Patients Would Be Suitable for Neoadjuvant Chemotherapy Followed by Fertility-Sparing Surgery?
The number of patients given neoadjuvant chemotherapy (NAC) followed by fertility-sparing surgery in cervical cancer is still scarce. Only a few centres perform these procedures, and thus, such procedures remain largely in the experimental stage. Patients that do not fulfil the criteria for standard fertility-sparing procedure can be included in studies with NAC followed by fertility-sparing procedure. We must consider that both oncological and pregnancy outcomes are important. Patients with only microscopic disease after NAC are apparently the best candidates for fertility-sparing surgery. Current data are not sufficient to identify the optimal procedure after NAC [abdominal radical trachelectomy (ART) or vaginal radical trachelectomy (VRT) or simple trachelectomy]. Some evidence suggests that pregnancy outcome is better after simple trachelectomy as compared with VRT or ART. Long-term results regarding oncological outcome for this concept are still lacking. Adjuvant chemotherapy in patients with histopathological risk factors (lymphovascular space involvement (LVSI), macroscopic residual disease) would decrease a risk of recurrence.
- 1 March 2015
- Published by Elsevier in Human Immunology
- Vol. 76 (2-3) , 187-191
Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients
- 1 March 2015
- Published by Elsevier in Human Immunology
- Vol. 76 (2-3) , 187-191
Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients
- 1 November 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 135 (2) , 213-216
Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer
- 1 November 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 135 (2) , 213-216
Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer
- 1 July 2013
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 13 (7) , 861-870
Current status of sentinel lymph node mapping in the management of cervical cancer
The status of regional lymph nodes is the most important prognostic factor in early cervical cancer patients. Pelvic lymph node dissections are routinely performed as a part of standard surgical treatment. Systematic pelvic lymphadenectomy is associated with short- and long-term morbidities. This review discusses single components of the sentinel lymph node mapping (SLNM) technique and results of the detection of sentinel lymph nodes. SLNM biopsy performed by an experienced team for small volume tumors (<2 cm) has high specific side detection rate, excellent negative-predictive value and high sensitivity. Uncommon lymphatic drainage has been reported in 15% of cervical cancer patients. There is sufficient data now to suggest that SLNM with 99mTc plus blue dye in the hands of a surgeon with extensive experience should prove to be an important part of individualized cervical cancer surgery and increase the safety of less radical or fertility-sparing surgery.
- 1 July 2013
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 13 (7) , 861-870
Current status of sentinel lymph node mapping in the management of cervical cancer
The status of regional lymph nodes is the most important prognostic factor in early cervical cancer patients. Pelvic lymph node dissections are routinely performed as a part of standard surgical treatment. Systematic pelvic lymphadenectomy is associated with short- and long-term morbidities. This review discusses single components of the sentinel lymph node mapping (SLNM) technique and results of the detection of sentinel lymph nodes. SLNM biopsy performed by an experienced team for small volume tumors (<2 cm) has high specific side detection rate, excellent negative-predictive value and high sensitivity. Uncommon lymphatic drainage has been reported in 15% of cervical cancer patients. There is sufficient data now to suggest that SLNM with 99mTc plus blue dye in the hands of a surgeon with extensive experience should prove to be an important part of individualized cervical cancer surgery and increase the safety of less radical or fertility-sparing surgery.
- 1 January 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 128 (1) , 49-53
High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer
- 1 January 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 128 (1) , 49-53
High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer
- 1 December 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (12) , 781-783
A Prospective Study in Detection of Lower-Limb Lymphedema and Evaluation of Quality of Life After Vulvar Cancer Surgery
- 1 December 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (12) , 781-783
A Prospective Study in Detection of Lower-Limb Lymphedema and Evaluation of Quality of Life After Vulvar Cancer Surgery
- 12 June 2012
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 28 (6) , 489-500
Surgical options in early cervical cancer
Cancer of the cervix is the second most common cancer in women worldwide and the fourth leading cause of cancer mortality in women. Early cervical cancer stage IB1 includes a broad range of disease from clinically undetectable microinvasive cancer to bulky tumours that infiltrated the entire cervix. This article reviews the literature about risk factors and surgical radicality and fertility-sparing surgery in early cervical cancer. The review evaluates selection criteria, preoperative management and the most frequent surgical procedures used for individually tailored surgery for cervical cancer.
- 12 June 2012
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 28 (6) , 489-500
Surgical options in early cervical cancer
Cancer of the cervix is the second most common cancer in women worldwide and the fourth leading cause of cancer mortality in women. Early cervical cancer stage IB1 includes a broad range of disease from clinically undetectable microinvasive cancer to bulky tumours that infiltrated the entire cervix. This article reviews the literature about risk factors and surgical radicality and fertility-sparing surgery in early cervical cancer. The review evaluates selection criteria, preoperative management and the most frequent surgical procedures used for individually tailored surgery for cervical cancer.
- 1 February 2011
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (2) , 192-200
Fertility-sparing surgery in patients with cervical cancer
- 1 February 2011
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (2) , 192-200
Fertility-sparing surgery in patients with cervical cancer
- 31 December 2010
- Published by Elsevier in Clinical Immunology
- Vol. 135, S54
TumorAntigenExpressioninPrimaryOvarianCancerCells
- 31 December 2010
- Published by Elsevier in Clinical Immunology
- Vol. 135, S54
TumorAntigenExpressioninPrimaryOvarianCancerCells
- 1 July 2010
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 10 (7) , 1101-1114
Advances in fertility-sparing surgery for cervical cancer
(2010). Advances in fertility-sparing surgery for cervical cancer. Expert Review of Anticancer Therapy: Vol. 10, No. 7, pp. 1101-1114. doi: 10.1586/era.10.61
- 1 July 2010
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 10 (7) , 1101-1114
Advances in fertility-sparing surgery for cervical cancer
(2010). Advances in fertility-sparing surgery for cervical cancer. Expert Review of Anticancer Therapy: Vol. 10, No. 7, pp. 1101-1114. doi: 10.1586/era.10.61